Zacks Research Issues Optimistic Outlook for Azitra Earnings

Azitra, Inc. (NYSEAMERICAN:AZTR) – Investment analysts at Zacks Research raised their Q3 2026 earnings per share estimates for shares of Azitra in a research report issued to clients and investors on Monday, September 28th. Zacks Research analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.02) for the quarter, up from their previous forecast of ($0.04). The consensus estimate for Azitra’s current full-year earnings is ($0.20) per share. Zacks Research also issued estimates for Azitra’s Q4 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at ($0.06) EPS.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05).

Azitra Stock Performance

Azitra stock opened at $0.13 on Thursday. The business has a 50-day moving average of $0.15 and a 200-day moving average of $0.18. Azitra has a 1 year low of $0.10 and a 1 year high of $1.09.

Azitra Company Profile

Azitra, Inc is a clinical-stage biotechnology company focused on developing precision dermatology treatments for inflammatory and other skin conditions. The company uses engineered microbes and its proprietary platform to discover and develop live biotherapeutic products intended to address disease-related changes in the skin microbiome and deliver therapeutic proteins locally.

Azitra’s product pipeline has included ATR-12, an engineered strain of Staphylococcus epidermidis designed to produce filaggrin-1 for the potential treatment of Netherton syndrome, a rare genetic skin disorder.